Compare HubSpot Inc (HUBS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Pfizer Inc — how do they compare? HubSpot Inc trades at $230.63 (market cap $11.56B), while Pfizer Inc trades at $27.86 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 13.7× HubSpot Inc's market cap, and Pfizer Inc pays a 6.18% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Pfizer Inc for 158 Days on average.
| HUBS | PFE | |
|---|---|---|
Market Cap | $11.56B | $158.56B |
Volume | 1,891,287 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $494.58 | $29.02 |
52-Week Low | $170.39 | $23.67 |
Typical Hold Time | 78 Days | 158 Days |
Enterprise Value | $10.46B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $233.94, up 6.19% today, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $3.26, beating estimates of $3.02, continuing a trend of positive surprises. Revenue growth is robust, with 2025 revenue at $3.13 billion, and net income turning positive at $45.91 million. Analyst sentiment remains largely positive with a consensus price target of $243.65, though valuation multiples like a P/E of 82.51 are elevated. Recent news highlights AI strategy advancements and partnerships, including a deepened collaboration with OpenAI.
The outlook for HUBS is cautiously optimistic, driven by strong revenue growth, margin expansion potential, and strategic AI initiatives. Key risks include high valuation multiples, competitive pressures in the CRM space, and potential demand headwinds from economic conditions. Institutional ownership trends show significant interest, such as the California State Teachers Retirement System increasing its stake. The stock presents a growth opportunity but requires monitoring of execution risks and market sentiment shifts.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
